secwatch.observer — SEC 8-K summary
======================================

Issuer:     Quoin Pharmaceuticals, Ltd. (QNRX)
CIK:        0001671502
Form:       8-K
Filed at:   2024-12-19T23:59:59+00:00
Accession:  0001104659-24-130017
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Quoin Pharma gets FDA clearance for whole-body QRX003 study in Netherton Syndrome
--------------------------------------------------------------------------------

- FDA clearance for new Netherton Syndrome study of QRX003 applied to >80% BSA twice daily for 12 weeks in up to 8 patients.
- Prior studies used ~20% BSA; new whole-body design mimics real-world use to support potential regulatory approval.
- Study led by Dr. Amy Paller at Northwestern University; data to supplement QRX003 NDA package.
- Quoin is a clinical-stage specialty pharma focused on rare/orphan diseases; stock trades as QNRX.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1671502/000110465924130017/0001104659-24-130017-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1671502/000110465924130017/tm2431545d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-130017

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer